JP2010530359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530359A5 JP2010530359A5 JP2010508353A JP2010508353A JP2010530359A5 JP 2010530359 A5 JP2010530359 A5 JP 2010530359A5 JP 2010508353 A JP2010508353 A JP 2010508353A JP 2010508353 A JP2010508353 A JP 2010508353A JP 2010530359 A5 JP2010530359 A5 JP 2010530359A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- nrp1
- nrp2
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 47
- 101150106321 Nrp2 gene Proteins 0.000 claims description 37
- 101150051337 NRP1 gene Proteins 0.000 claims description 36
- 239000005557 antagonist Substances 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 32
- 239000013078 crystal Substances 0.000 claims description 31
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 28
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 28
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 28
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
- 230000005855 radiation Effects 0.000 claims description 16
- 108050003978 Semaphorin Proteins 0.000 claims description 14
- 102000014105 Semaphorin Human genes 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 12
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 230000004071 biological effect Effects 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 6
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 6
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 6
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 6
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 6
- 229960000241 vandetanib Drugs 0.000 claims description 6
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 4
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- BRVFNEZMTRVUGW-QFIPXVFZSA-N (2s)-2-[6-[(3-methyl-1-oxo-4h-benzo[f]quinazolin-9-yl)methylamino]-3-oxo-1h-isoindol-2-yl]pentanedioic acid Chemical compound C1=C2C(=O)N([C@@H](CCC(O)=O)C(O)=O)CC2=CC(NCC2=CC=C3C=CC4=C(C3=C2)C(=O)N=C(N4)C)=C1 BRVFNEZMTRVUGW-QFIPXVFZSA-N 0.000 claims description 3
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 3
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims description 3
- 229960005557 OSI-7904 Drugs 0.000 claims description 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960002412 cediranib Drugs 0.000 claims description 3
- 229960001433 erlotinib Drugs 0.000 claims description 3
- 229960002584 gefitinib Drugs 0.000 claims description 3
- 229940080856 gleevec Drugs 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- 229960004891 lapatinib Drugs 0.000 claims description 3
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 3
- 229950010895 midostaurin Drugs 0.000 claims description 3
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims description 3
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims description 3
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 3
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- 229960001796 sunitinib Drugs 0.000 claims description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 3
- 229940034785 sutent Drugs 0.000 claims description 3
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 claims description 3
- 229940120982 tarceva Drugs 0.000 claims description 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 3
- 229940099039 velcade Drugs 0.000 claims description 3
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 229940119473 Semaphorin antagonist Drugs 0.000 claims description 2
- 208000032594 Vascular Remodeling Diseases 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000010807 negative regulation of binding Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229960003876 ranibizumab Drugs 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 229950000578 vatalanib Drugs 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2007/069185 WO2008143666A2 (en) | 2007-05-17 | 2007-05-17 | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012180233A Division JP5207564B2 (ja) | 2012-08-15 | 2012-08-15 | ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造 |
| JP2012180232A Division JP5723840B2 (ja) | 2012-08-15 | 2012-08-15 | ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530359A JP2010530359A (ja) | 2010-09-09 |
| JP2010530359A5 true JP2010530359A5 (enExample) | 2011-05-12 |
Family
ID=38963109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010508353A Withdrawn JP2010530359A (ja) | 2007-05-17 | 2007-05-17 | ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8318163B2 (enExample) |
| EP (1) | EP2158215B1 (enExample) |
| JP (1) | JP2010530359A (enExample) |
| KR (1) | KR101523788B1 (enExample) |
| CN (1) | CN101743253B (enExample) |
| AU (1) | AU2007353779B2 (enExample) |
| BR (1) | BRPI0721707A2 (enExample) |
| CA (1) | CA2687556A1 (enExample) |
| ES (1) | ES2541051T3 (enExample) |
| IL (1) | IL201983A (enExample) |
| MX (1) | MX2009012282A (enExample) |
| RU (1) | RU2012109383A (enExample) |
| WO (1) | WO2008143666A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| CN103080136B (zh) * | 2010-06-18 | 2015-08-12 | 霍夫曼-拉罗奇有限公司 | 抗Axl抗体及使用方法 |
| WO2012123755A1 (en) | 2011-03-17 | 2012-09-20 | The University Of Birmingham | Re-directed immunotherapy |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| CN103992377B (zh) * | 2013-02-18 | 2017-05-17 | 上海市第一人民医院 | 一种抑制新生血管的小肽及其应用 |
| CN103992376B (zh) * | 2013-02-18 | 2017-05-17 | 上海市第一人民医院 | 一种抑制新生血管的小肽及其应用 |
| CN114717206A (zh) | 2013-03-15 | 2022-07-08 | Atyr 医药公司 | 组氨酰-trna合成酶-fc缀合物 |
| JP2017518307A (ja) | 2014-06-02 | 2017-07-06 | チルドレンズ メディカル センター コーポレーション | 免疫調節のための方法および組成物 |
| AU2015311563B2 (en) * | 2014-09-05 | 2019-11-28 | Rsem, Limited Partnership | Compositions and methods for treating and preventing inflammation |
| EP3401331B1 (en) | 2016-01-06 | 2022-04-06 | Order-Made Medical Research Inc. | High-affinity anti-vegf antibody |
| WO2017119434A1 (ja) | 2016-01-06 | 2017-07-13 | 株式会社オーダーメードメディカルリサーチ | Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体 |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| JOP20190134A1 (ar) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها |
| ES2994451T3 (en) | 2017-04-20 | 2025-01-24 | Atyr Pharma Inc | Compositions for treating lung inflammation |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| JP2020522562A (ja) * | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー．， インコーポレイテッド | Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
| WO2019195770A1 (en) * | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| JP7728701B2 (ja) | 2018-12-17 | 2025-08-25 | レビトープ リミテッド | 双子型免疫細胞エンゲージャー |
| TWI859339B (zh) | 2019-09-24 | 2024-10-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 |
| AU2020358854B2 (en) | 2019-10-03 | 2026-08-13 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| GB202207116D0 (en) * | 2022-05-16 | 2022-06-29 | Quadram Inst Bioscience | Method and Compositions for Tumorigenesis Inhibition |
| CN114949224B (zh) * | 2022-06-06 | 2023-03-14 | 山东大学第二医院 | Nrp2激动剂在制备复发性流产治疗药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1990004788A1 (en) | 1988-10-28 | 1990-05-03 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| KR100335584B1 (ko) | 1992-10-28 | 2002-11-29 | 제넨테크, 인코포레이티드 | 혈관내피세포성장인자에대한길항제 |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| CN104231078A (zh) | 1997-04-07 | 2014-12-24 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
-
2007
- 2007-05-17 ES ES07762242.1T patent/ES2541051T3/es active Active
- 2007-05-17 JP JP2010508353A patent/JP2010530359A/ja not_active Withdrawn
- 2007-05-17 KR KR1020097026233A patent/KR101523788B1/ko not_active Expired - Fee Related
- 2007-05-17 US US12/598,625 patent/US8318163B2/en not_active Expired - Fee Related
- 2007-05-17 CA CA002687556A patent/CA2687556A1/en not_active Abandoned
- 2007-05-17 MX MX2009012282A patent/MX2009012282A/es active IP Right Grant
- 2007-05-17 AU AU2007353779A patent/AU2007353779B2/en not_active Ceased
- 2007-05-17 BR BRPI0721707-2A patent/BRPI0721707A2/pt not_active IP Right Cessation
- 2007-05-17 CN CN2007800537931A patent/CN101743253B/zh not_active Expired - Fee Related
- 2007-05-17 WO PCT/US2007/069185 patent/WO2008143666A2/en not_active Ceased
- 2007-05-17 EP EP20070762242 patent/EP2158215B1/en active Active
-
2009
- 2009-11-08 IL IL201983A patent/IL201983A/en not_active IP Right Cessation
-
2012
- 2012-03-12 RU RU2012109383/10A patent/RU2012109383A/ru not_active Application Discontinuation
- 2012-07-03 US US13/541,411 patent/US8466264B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2425842C2 (ru) | Антагонисты нейропилина | |
| RU2349340C2 (ru) | Биспецифические антитела к erb-b и их применение для лечения опухолей | |
| JP2013510868A5 (enExample) | ||
| HRP20200921T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3 | |
| JP2020522513A5 (enExample) | ||
| Dokurno et al. | Crystal structure at 1.95 Å resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition | |
| JP2013529059A5 (enExample) | ||
| JP2020527136A (ja) | チェックポイントインヒビター二重特異性抗体 | |
| JP2021524268A5 (enExample) | ||
| JP2022542431A5 (enExample) | ||
| JP2004534020A5 (enExample) | ||
| JP2005522514A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| JP2020504723A5 (enExample) | ||
| RU2008101772A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| IL272349B2 (en) | ANTI-CD137 antibodies | |
| JP2008531576A5 (enExample) | ||
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| JP2010531140A5 (enExample) | ||
| JPWO2021177438A5 (enExample) | ||
| RU2003123781A (ru) | Комбинированная терапия, использующая ингибиторы рецептора тирозинкиназы и ингибиторы ангиогенезиса | |
| JP2015536933A5 (enExample) | ||
| JP2025503322A5 (enExample) |